Document is current
Any future updates will be listed below
-
Authors
Marcondes, Giulianna B.
Tenorio, Emanuel R.
Baumgardt, Guilherme
Mendes, Bernardo
Oderich, Gustavo S.
- License Information
-
More Information
Article History
Received: 1 June 2021
Accepted: 12 October 2021
First Online: 27 October 2021
Declarations
:
: Gustavo Oderich MD has received consulting fees and grants from Cook Medical, W. L. Gore, and GE Healthcare (all paid to Mayo Clinic with no personal income). Other co-authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This is a retrospective review of a prospective maintained database of patients treated by FB-EVAR conducted under the US Food and Drug Administration (FDA) PS-IDE G130030 and G130266 and registered under <i>ClinicalTrial.gov</i> NCT01937949 and NCT02089607. The study was approved by the Institutional Review Board at University of Texas Health Science Center at Houston and Mayo Clinic Rochester.
: For this type of study, consent for publication is not required.
: Informed consent was obtained from all individual participants included in the study.
